ExonHit Therapeutics, a drug and diagnostic discovery company, has announced that a number of its SpliceArray products are now available on the Affymetrix microarray platform.
SpliceArrays are a new generation of microarrays that resolve the expression of genes at the level of their alternatively spliced transcripts. Recent publications suggest that over 80% of all human genes undergo alternative splicing, potentially producing many gene products with different functions from a single locus. With the perceived importance of alternative splicing at an all time high, the need for robust and accurate tools specifically designed to fully interrogate the complete transcriptome is critical for a clearer understanding of the onset of diseases and regulation of biological processes. ExonHit’s SpliceArray content and patented probe configuration achieve this goal, claims the company.
This announcement means that SpliceArray products are now available on both Agilent and Affymetrix microarray platforms, the two main platforms used routinely in the fields of on-going research, drug discovery and diagnostics.